# Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis

> **NCT04130919** · PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 19 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Tilpisertib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04130919
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-20
- **Primary completion:** 2021-02-25
- **Final completion:** 2021-12-14
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Sponsor terminated the study since a new molecular entity was able to achieve greater target coverage
- **Last updated:** 2022-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04130919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04130919, "Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04130919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*